SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 1, 2003; DOI 10.1182/blood-2002-12-3789. This Article Full Text (PDF) All Versions of this Article: 2002-12-3789v1 102/5/1588    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Soverini, S. Articles by Martinelli, G. Search for Related Content PubMed PubMed Citation Articles by Soverini, S. Articles by Martinelli, G. Related Collections Related Letter in Blood Online Social Bookmarking                   What's this? Submitted December 16, 2002 Accepted April 18, 2003 Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Simona Soverini, Michele Cavo*, Carolina Terragna, Elena Zamagni, Deborah Ruggeri, Claudia Cellini, Nicoletta Testoni, Patrizia Tosi, Antonio de Vivo, Marilina Amabile, Tiziana Grafone, Emanuela Ottaviani, Barbara Giannini, Delia Cangini, Francesca Bonifazi, Antonino Neri, Sonia Fabris, Sante Tura, Michele Baccarani, and Giovanni Martinelli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy Servizio di Ematologia, Ospedale Maggiore IRCCS, Milan, Italy * Corresponding author; email: mcavo{at}med.unibo.it. We used a sensitive real-time RT-PCR assay to quantify cyclin D1 mRNA levels in bone marrow samples collected at diagnosis from 74 newly diagnosed multiple myeloma (MM) patients who were randomized to receive either single or double peripheral blood stem cell autotransplants as part of first-line therapy for their malignancy. In 46 cases, conventional cytogenetics and eventually added FISH analysis were performed to detect chromosome 11 abnormalities. Patients with the t(11;14) or trisomy 11 significantly overexpressed cyclin D1 (P<0.00001) in comparison with patients without 11q abnormalities, who had cyclin D1 mRNA levels similar to healthy donors. Overall, 32/74 (43%) patients showed cyclin D1 overexpression. No difference was found between cyclin D1 positive (group A) and cyclin D1 negative (group B) patients with respect to presenting clinical and laboratory characteristics, including chromosome 13 abnormalities, as well as to response to therapy and overall survival, both of whom were calculated on an intent-to-treat basis. Patients who overexpressed cyclin D1 had significantly longer duration of remission in comparison with patients who did not (41 vs 26 months, respectively; P=0.02). As a result, median even-free survival (EFS) was longer in group A than in group B (33 vs. 24 months, respectively; P=0.055). It is concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autotransplant(s). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Relevance of cyclin D1 level in the pathogenesis of multiple myeloma Brigitte Sola, Xavier Troussard, Simona Soverini, Giovanni Martinelli, and Michele Cavo Blood 2003 102: 4245-4246. [Full Text] [PDF] This article has been cited by other articles: N-T Ngo, C Brodie, C Giles, D Horncastle, M Klammer, I A Lampert, A Rahemtulla, and K N Naresh The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome J. Clin. Pathol., November 1, 2009; 62(11): 1009 - 1015. [Abstract] [Full Text] [PDF] M Deshmukh, K Elderfield, A Rahemtulla, and K N Naresh Immunophenotype of neoplastic plasma cells in AL amyloidosis J. Clin. Pathol., August 1, 2009; 62(8): 724 - 730. [Abstract] [Full Text] [PDF] M. A. Dawson, S. S. Opat, Y. Taouk, M. Donovan, M. Zammit, K. Monaghan, N. Horvath, A. W. Roberts, H. M. Prince, M. Hertzberg, et al. Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 714 - 722. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Di Raimondo, E. Volpe, S. Ronconi, D. Cangini, et al. Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study J. Clin. Oncol., June 10, 2007; 25(17): 2434 - 2441. [Abstract] [Full Text] [PDF] H. Biliran Jr., S. Banerjee, A. Thakur, F. H. Sarkar, A. Bollig, F. Ahmed, J. Wu, Y. Sun, and J. D. Liao c-Myc Induced Chemosensitization Is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-{kappa}B Activity in Pancreatic Cancer Cells Clin. Cancer Res., May 1, 2007; 13(9): 2811 - 2821. [Abstract] [Full Text] [PDF] G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood, April 15, 2007; 109(8): 3177 - 3188. [Abstract] [Full Text] [PDF] F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF] L. B. Baughn, M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A.S. Moore, et al. A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res., August 1, 2006; 66(15): 7661 - 7667. [Abstract] [Full Text] [PDF] M. Cavo, C. Terragna, M. Renzulli, E. Zamagni, P. Tosi, N. Testoni, C. Nicci, D. Cangini, P. Tacchetti, T. Grafone, et al. Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission J. Clin. Oncol., January 20, 2006; 24(3): e4 - e5. [Full Text] [PDF] S. Ely, M. Di Liberto, R. Niesvizky, L. B. Baughn, H. J. Cho, E. N. Hatada, D. M. Knowles, J. Lane, and S. Chen-Kiang Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma Cancer Res., December 15, 2005; 65(24): 11345 - 11353. [Abstract] [Full Text] [PDF] M. A. Gertz, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, M. R. Litzow, K. J. Henderson, S. A. Van Wier, G. J. Ahmann, and R. Fonseca Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood, October 15, 2005; 106(8): 2837 - 2840. [Abstract] [Full Text] [PDF] L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations J. Clin. Oncol., October 10, 2005; 23(29): 7296 - 7306. [Abstract] [Full Text] [PDF] H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma Blood, July 15, 2005; 106(2): 706 - 712. [Abstract] [Full Text] [PDF] P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood, July 1, 2005; 106(1): 296 - 303. [Abstract] [Full Text] [PDF] K. Specht, E. Haralambieva, K. Bink, M. Kremer, S. Mandl-Weber, I. Koch, R. Tomer, H. Hofler, E. Schuuring, P. M. Kluin, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels Blood, August 15, 2004; 104(4): 1120 - 1126. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF] B. Sola, X. Troussard, S. Soverini, G. Martinelli, and M. Cavo Relevance of cyclin D1 level in the pathogenesis of multiple myeloma Blood, December 1, 2003; 102(12): 4245 - 4246. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020